loading
Tiziana Life Sciences Ltd stock is traded at $1.36, with a volume of 348.22K. It is down -5.56% in the last 24 hours and up +10.57% over the past month. Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.
See More
Previous Close:
$1.44
Open:
$1.43
24h Volume:
348.22K
Relative Volume:
0.39
Market Cap:
$132.04M
Revenue:
-
Net Income/Loss:
$-13.73M
P/E Ratio:
-10.46
EPS:
-0.13
Net Cash Flow:
$-3.92M
1W Performance:
+27.10%
1M Performance:
+10.57%
6M Performance:
+37.33%
1Y Performance:
+61.69%
1-Day Range:
Value
$1.29
$1.43
1-Week Range:
Value
$1.01
$1.53
52-Week Range:
Value
$0.5437
$1.91

Tiziana Life Sciences Ltd Stock (TLSA) Company Profile

Name
Name
Tiziana Life Sciences Ltd
Name
Phone
-
Name
Address
-
Name
Employee
9
Name
Twitter
@tizianals
Name
Next Earnings Date
2024-05-27
Name
Latest SEC Filings
Name
TLSA's Discussions on Twitter

Compare TLSA with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
TLSA
Tiziana Life Sciences Ltd
1.36 132.04M 0 -13.73M -3.92M -0.13
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
493.84 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
602.64 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
614.76 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.56 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
244.90 24.70B 3.81B -644.79M -669.77M -6.24

Tiziana Life Sciences Ltd Stock (TLSA) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-22-20 Initiated B. Riley Securities Buy
Dec-17-18 Initiated Laidlaw Buy

Tiziana Life Sciences Ltd Stock (TLSA) Latest News

pulisher
Apr 24, 2025

Dosing begins in Tiziana Life Sciences’ trial of foralumab for na-SPMS - Yahoo Finance

Apr 24, 2025
pulisher
Apr 24, 2025

How to interpret Tiziana Life Sciences Ltd (TLSA)’s stock chart patterns - uspostnews.com

Apr 24, 2025
pulisher
Apr 24, 2025

Tiziana Life Sciences Ltd: A Comprehensive Look at the Stock’s Ups and Downs - investchronicle.com

Apr 24, 2025
pulisher
Apr 23, 2025

Small cap wrap: Tiziana Life Sciences, Excellon Resources, Lancaster Resources... - Proactive Investors

Apr 23, 2025
pulisher
Apr 23, 2025

Tiziana Life Sciences Announces University of Massachusetts Starts Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial - marketscreener.com

Apr 23, 2025
pulisher
Apr 23, 2025

Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial - The Manila Times

Apr 23, 2025
pulisher
Apr 23, 2025

Breakthrough MS Treatment Trial: UMass Joins Harvard, Yale, Johns Hopkins Testing Home-Use Nasal Drug - Stock Titan

Apr 23, 2025
pulisher
Apr 23, 2025

Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2… - Informazione.it

Apr 23, 2025
pulisher
Apr 23, 2025

Tiziana Life Sciences announces patient dosing in Phase 2 MS trial - Proactive financial news

Apr 23, 2025
pulisher
Apr 08, 2025

Multiple sclerosis Pipeline Analysis and Clinical Trials - openPR.com

Apr 08, 2025
pulisher
Apr 02, 2025

TLSATiziana Life Sciences Ltd Com Latest Stock News & Market Updates - Stock Titan

Apr 02, 2025
pulisher
Apr 02, 2025

Small cap wrap: Zero Candida, Midnight Sun Mining, Tiziana Life Sciences, Trust Stamp... - Proactive financial news

Apr 02, 2025
pulisher
Apr 02, 2025

Tiziana Life Sciences begins patient dosing in Phase 2 MS trial at Johns Hopkins - Proactive financial news

Apr 02, 2025
pulisher
Apr 02, 2025

Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab In Phase 2 Multiple Sclerosis Clinical Trial - MarketScreener

Apr 02, 2025
pulisher
Apr 02, 2025

Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial - The Manila Times

Apr 02, 2025
pulisher
Apr 02, 2025

Major Breakthrough: Johns Hopkins Launches Novel Nasal Treatment in Phase 2 MS Trial - Stock Titan

Apr 02, 2025
pulisher
Mar 26, 2025

Tiziana Life Sciences begins dosing in trial of therapy for multiple sclerosis - Yahoo Finance

Mar 26, 2025
pulisher
Mar 26, 2025

Tiziana Life Sciences begins dosing in Phase 2 trial for intranasal foralumab in SPMS - Proactive financial news

Mar 26, 2025
pulisher
Mar 25, 2025

Small cap wrap: Northern Superior Resources, Tiziana Life Sciences, Alternus Clean Energy... - Proactive Investors

Mar 25, 2025
pulisher
Mar 25, 2025

Multiple sclerosis Clinical Trials and Studies 2025: EMA, PDMA, - openPR

Mar 25, 2025
pulisher
Mar 25, 2025

Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial - The Manila Times

Mar 25, 2025
pulisher
Mar 25, 2025

Yale Launches Groundbreaking Intranasal MS Treatment Trial: Tiziana's Innovation in Focus - Stock Titan

Mar 25, 2025
pulisher
Mar 24, 2025

Tiziana Life Sciences Ltd Files For Mixed Shelf Of Up To $250 MillionSEC Filing -March 24, 2025 at 05:22 pm EDT - Marketscreener.com

Mar 24, 2025
pulisher
Mar 17, 2025

Tiziana Life Sciences CEO to present at 37th Annual ROTH Conference - Proactive Investors UK

Mar 17, 2025
pulisher
Mar 17, 2025

Tiziana Life Sciences to Present at the 37th Annual Roth Conference - The Manila Times

Mar 17, 2025
pulisher
Mar 17, 2025

Tiziana Life Sciences Reveals Growth Strategy at Major ROTH ConferenceKey Updates Expected - StockTitan

Mar 17, 2025
pulisher
Mar 14, 2025

Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule - The Manila Times

Mar 14, 2025
pulisher
Mar 14, 2025

Tiziana Life Sciences Regains Compliance with Nasdaq Listing Requirements - Nasdaq

Mar 14, 2025
pulisher
Mar 14, 2025

Tiziana Life Sciences Regains Compliance With Nasdaq Listing Minimum Bid Price Rule - MENAFN.COM

Mar 14, 2025
pulisher
Mar 14, 2025

Tiziana Life Sciences Dodges Delisting: How Company Saved Its Nasdaq Status - Stock Titan

Mar 14, 2025
pulisher
Mar 13, 2025

Oramed Pharmaceuticals And 2 Other Penny Stocks With Promising Potential - Simply Wall St

Mar 13, 2025
pulisher
Mar 10, 2025

Tiziana Life Sciences Announces TV Interview with First Patient Dosed with Moderate Alzheimer's Disease - Informazione.it

Mar 10, 2025
pulisher
Mar 10, 2025

Can Tiziana's Foralumab Enable Breakthroughs In Neuroinflammatory And Neurodegenerative Diseases? - RTTNews

Mar 10, 2025
pulisher
Mar 07, 2025

Tiziana Life Sciences stock soars to 52-week high of $1.75 - Investing.com

Mar 07, 2025
pulisher
Mar 06, 2025

Democrat-led states join legal fight over Trump's mass firings of federal workers -March 06, 2025 at 10:38 pm EST - Marketscreener.com

Mar 06, 2025
pulisher
Mar 06, 2025

Tiziana Life Sciences Ltd. (NASDAQ: TLSA) Stock Hits Multi-Month High After Filing a Key IND with the FDA - DRP Journal

Mar 06, 2025
pulisher
Mar 05, 2025

Tiziana: Foralumab Drug Development Presses On With Additional EAP Enrollment - Seeking Alpha

Mar 05, 2025
pulisher
Mar 04, 2025

Sector Update: Health Care -March 04, 2025 at 03:39 pm EST - Marketscreener.com

Mar 04, 2025
pulisher
Mar 04, 2025

Tiziana submits FDA investigational new drug application - Proactive Investors UK

Mar 04, 2025
pulisher
Mar 04, 2025

Tiziana Life Sciences Files New Drug Application for ALS Drug Candidate -March 04, 2025 at 09:03 am EST - Marketscreener.com

Mar 04, 2025
pulisher
Mar 04, 2025

Tiziana Life Sciences Advances ALS Treatment with FDA IND Submission - TipRanks

Mar 04, 2025
pulisher
Mar 04, 2025

Tiziana Life Sciences Files Investigational New Drug Application With FDA For ALS Phase 2 Clinical Trial - Marketscreener.com

Mar 04, 2025
pulisher
Mar 04, 2025

Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial - The Manila Times

Mar 04, 2025
pulisher
Mar 04, 2025

Could This Intranasal Therapy Change ALS Treatment? Tiziana Seeks FDA Approval - StockTitan

Mar 04, 2025
pulisher
Mar 04, 2025

Tiziana Life Sciences Ltd (NASDAQ:TLSA) Sees Significant Drop in Short Interest - Defense World

Mar 04, 2025
pulisher
Mar 03, 2025

AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week - MSN

Mar 03, 2025
pulisher
Mar 02, 2025

Why Tiziana Life Sciences Ltd (TLSA) is Skyrocketing So Far in 2025 - Insider Monkey

Mar 02, 2025
pulisher
Mar 01, 2025

Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025 - Insider Monkey

Mar 01, 2025
pulisher
Feb 27, 2025

Tiziana stock jumps 12% on TBI drug study publication - MSN

Feb 27, 2025
pulisher
Feb 27, 2025

Tiziana Life Sciences' lead candidate demonstrates favorable safety profile and clinical response - Proactive Investors UK

Feb 27, 2025
pulisher
Feb 27, 2025

Market movers: Ideal Power, Tiziana Life Sciences, Medicus Pharma... - Proactive financial news

Feb 27, 2025

Tiziana Life Sciences Ltd Stock (TLSA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.59
price up icon 0.24%
$69.69
price up icon 1.06%
$32.20
price up icon 0.53%
$23.46
price down icon 36.06%
$102.02
price down icon 15.36%
biotechnology ONC
$244.90
price down icon 4.40%
Cap:     |  Volume (24h):